Treatment of dystonia

References

• Oppenheim H. Dysbasia lordotica progressiva, dystonia musculorum deformans. Neurol. Centrabl.30, 1090–1107 (1911).
   Google Scholar
• Flatau E, Sterling W. Progressiver Torsionspasms bie Kindern. Z Gesamte. Neurol. Psychiatr.7, 586–612 (1911).
   Google Scholar
• Fahn S. Concept and classification of dystonia. Adv. Neurol.50, 1–8 (1988).
   PubMedGoogle Scholar
• Hallett M. Physiology of dystonia. Adv. Neurol.78, 11–18 (1998).
   Google Scholar
• Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD. The pathophysiology of primary dystonia. Brain121, 1195–1212 (1998).
   PubMed Web of Science ®Google Scholar
• Schramm A, Reiners K, Naumann M. Complex mechanisms of sensory tricks in cervical dystonia. Mov. Disord.19, 452–458 (2004).
   PubMed Web of Science ®Google Scholar
• Marsden CD, Harrison MJG. Idiopathic torsion dystonia. Brain97, 793–810 (1974).
   PubMed Web of Science ®Google Scholar
• Bressman SB, de Leon D, Brin MF et al. Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann. Neurol.26(5), 612–620 (1989).
   PubMed Web of Science ®Google Scholar
• Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov. Disord.10(2), 143–152 (1995).
   PubMed Web of Science ®Google Scholar
• Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv. Neurol.78, 1–10 (1998).
   PubMedGoogle Scholar
• Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv. Neurol.94, 101–107 (2004).
   PubMedGoogle Scholar
• Hartmann A, Pogarell O, Oertel WH. Secondary dystonias. J. Neurol.245(8), 511–518 (1998).
   PubMed Web of Science ®Google Scholar
• Manji H, Howard RS, Miller DH et al. Status dystonicus: the syndrome and its management. Brain121(Pt 2), 243–252 (1998).
   PubMed Web of Science ®Google Scholar
• Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology35(1), 73–77 (1985).
   PubMed Web of Science ®Google Scholar
• Comella CL, Stebbins GT, Goetz C et al. Teaching tape for the motor section of the Toronto western spasmodic torticollis scale. Mov. Disord.12, 570–575 (1997).
   PubMedGoogle Scholar
• Consky ES, Lang AE. Clinical assessment of patients with cervical dystonia. In: Therapy with botulinum toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, NY, USA 211–223 (1994).
   Google Scholar
• Ondo WG, Desaloms JM, Jankovic J, Grossman RG. Pallidotomy for generalized dystonia. Mov. Disord.13(4), 693–698 (1998).
   PubMed Web of Science ®Google Scholar
• Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology36(2), 160–164 (1986).
   PubMed Web of Science ®Google Scholar
• Lindeboom R, de Haan RJ, Brans JWM et al. Treatment outcomes in cervical dystonia: a clinimetric study. Mov. Disord.11, 371–376 (1996).
   Google Scholar
• Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv. Neurol.94, 275–286 (2004).
   PubMedGoogle Scholar
• Goldman JG, Comella CL. Treatment of dystonia. Clin. Neuropharmacol.26(2), 102–108 (2003).
   PubMedGoogle Scholar
• Segawa M, Ohmi K, Itoh S et al. Childhood basal ganglia disease with remarkable response to L-dopa: hereditary basal ganglia disease with marked diurnal fluctuation (in Japanese). Shinryo (Tokyo)24, 667–672 (1971).
   Google Scholar
• Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv. Neurol.50, 377–384 (1988).
   PubMedGoogle Scholar
• Ichinose H, Ohye T, Takahashi E et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat. Genet.8, 236–242 (1994).
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology56(2), 260–263 (2001).
   PubMed Web of Science ®Google Scholar
• Hagenah J, Saunders-Pullman R, Hedrich K et al. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology64(5), 908–911 (2005).
   PubMed Web of Science ®Google Scholar
• Ichinose H, Suzuki T, Inagaki H, Ohye T, Nagatsu T. Molecular genetics of dopa-responsive dystonia. Biol. Chem.380, 1355–1364 (1999).
   Google Scholar
• Dewey RB, Muenter MD, Kishore A, Snow BJ. Long-term follow-up of levodopa responsiveness in generalized dystonia. Arch. Neurol.55, 1320–1323 (1998).
   Google Scholar
• Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology41, 174–181 (1991).
   PubMed Web of Science ®Google Scholar
• Nygaard TG, Takahashi H, Heiman G, Snow B, Fahn S, Calne D. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. Ann. Neurol.32, 603–608 (1992).
   Google Scholar
• Bandmann O, Nygaard TG, Surtees R, Marsden CD, Wood NW, Harding AE. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum. Mol. Genet.5(3), 403–406 (1996).
   Google Scholar
• Tassin J, Durr A, Bonnet AM et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain123, 1112–1121 (2000).
   Google Scholar
• Paviour DC, Surtees RAH, Lees AJ. Diagnostic considerations in juvenile parkinsonism. Mov. Disord.19, 123–135 (2004).
   Google Scholar
• de la Fuente-Fernandez R. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations. Clin. Neuropharmacol.22(4), 216–219 (1999).
   Google Scholar
• Bandmann O, Marsden CD, Wood NW. Atypical presentations of dopa-responsive dystonia. Adv. Neurol.78, 283–290 (1998).
   Google Scholar
• Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology40(1), 66–69 (1990).
   Google Scholar
• Nomura K, Yamamoto N, Takahashi I et al. [Bromocriptine and L-dopa therapy: comparison in a case of hereditary progressive dystonia with marked diurnal fluctuation]. No To Hattatsu19, 244–248 (1987).
   Google Scholar
• Fink JK, Ravin P, Argoff CE et al. Tetrahydrobiopterin administration in biopterin-deficient progressive dystonia with diurnal variation. Neurology39, 1393–1395 (1989).
   Web of Science ®Google Scholar
• LeWitt PA, Miller LP, Levine RA et al. Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. Neurology36(6), 760–764 (1986).
   Google Scholar
• Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur. J. Neurol.11(6), 361–370 (2004).
   PubMed Web of Science ®Google Scholar
• Defazio G, Lamberti P, Lepore V et al. Facial dystonia: clinical features, prognosis and pharmacology in 31 patients. Ital. J. Neurol. Sci.10, 553 (1989).
   Google Scholar
• Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov. Disord.3(1), 46–60 (1988).
   PubMed Web of Science ®Google Scholar
• Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv. Neurol.50, 547–556 (1988).
   PubMedGoogle Scholar
• Lang AE. Dopamine agonists in the treatment of dystonia. Clin. Neuropharmacol.8, 38 (1985).
   Google Scholar
• Tolosa ES. Modification of tardive dyskinesia and spasmodic torticollis by apomorphine. Arch. Neurol.35, 459 (1978).
   PubMedGoogle Scholar
• Silbergeld EK, Hruska RE. Lisuride and LSD: dopaminergic and serotonergic interactions in the "serotonin syndrome". Psychopharmacology65, 233 (1979).
   Google Scholar
• Stahl SM, Berger PA. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology32, 889–892 (1982).
   PubMed Web of Science ®Google Scholar
• Quinn NP, Lang AE, Sheehy MP, Marsden CD. Lisuride in dystonia. Neurology35, 766–769 (1985).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Hammerstad JP, Carter JH, deGarmo PL. Lisuride treatment of focal dystonias. Neurology35, 1242–1243 (1985).
   Google Scholar
• Obeso JA, Luquin MR. Bromocriptine and lisuride in dystonias. Neurology34, 135–136 (1984).
   Google Scholar
• Hoon AH Jr., Freese PO, Reinhardt EM et al. Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr. Neurol.25(1), 55–58 (2001).
   Google Scholar
• Jabbari B, Scherokman B, Gunderson CH, Rosenberg ML, Miller J. Treatment of movement disorders with trihexyphenidyl. Mov. Disord.4(3), 202–212 (1989).
   Google Scholar
• Fahn S. Treatment of dystonia with high-dose anticholinergic medication. Neurology29, 605 (1979).
   Web of Science ®Google Scholar
• Fahn S. High dosage anticholinergic therapy in dystonia. Neurology33(10), 1255–1261 (1983).
   PubMed Web of Science ®Google Scholar
• Lang AE. High dose anticholinergic therapy in adult dystonia. Can. J. Neurol. Sci.13(1), 42–46 (1986).
   PubMed Web of Science ®Google Scholar
• Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J. Neurol. Neurosurg. Psychiatry47(11), 1166–1173 (1984).
   PubMedGoogle Scholar
• Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv. Neurol.37, 189–192 (1983).
   PubMedGoogle Scholar
• Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov. Disord.1, 193 (1986).
   Google Scholar
• Taylor AE, Lang AE, Saint-Cyr JA, Riley DE, Ranawaya R. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clin. Neuropharmacol.14(1), 62–77 (1991).
   PubMed Web of Science ®Google Scholar
• Davidoff RA. Antispasticity drugs: mechanisms of action. Ann. Neurol.17(2), 107–116 (1985).
   PubMed Web of Science ®Google Scholar
• Seabrook GR, Howson W, Lacey MG. Electrophysiological characterization of potent agonists and antagonists at pre- and postsynaptic GABAb receptors on neurones in rat brain slices. Br. J. Pharmacol.101(4), 949–957 (1990).
   PubMedGoogle Scholar
• Bowery NG, Hill DR, Hudson AL et al. (-) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature283(5742), 92–94 (1980).
   PubMed Web of Science ®Google Scholar
• Anca MH, Zaccai TF, Badarna S, Lozano AM, Lang AE, Giladi N. Natural history of Oppenheim's dystonia (DYT1) in Israel. J. Child Neurol.18(5), 325–330 (2003).
   PubMedGoogle Scholar
• Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov. Disord.7(1), 48–52 (1992).
   PubMed Web of Science ®Google Scholar
• Greene P. Baclofen in the treatment of dystonia. Clin. Neuropharmacol.15(4), 276–288 (1992).
   PubMed Web of Science ®Google Scholar
• Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can. J. Ophthalmol.22(1), 24–28 (1987).
   PubMed Web of Science ®Google Scholar
• Knutsson E, Lindblom U, Martensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J. Neurol. Sci.23(3), 473–484 (1974).
   PubMed Web of Science ®Google Scholar
• Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal baclofen for intractable axial dystonia. Neurology41(7), 1141–1142 (1991).
   PubMed Web of Science ®Google Scholar
• Dressler D, Oeljeschlager RO, Ruther E. Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov. Disord.12, 585–587 (1997).
   Google Scholar
• Albright AL, Barry MJ, Painter MJ et al. Infusion of intrathecal baclofen for generalized dystonia in cerebral palsy. J. Neurosurg.88, 73–76 (1998).
   Google Scholar
• Albright AL, Barry MJ, Fasick P, Barron W, Shultz B. Continuous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery38(5), 934–938 (1996).
   PubMedGoogle Scholar
• Walker RH, Danisi FO, Swope DM, Goodman RR, Germano IM, Brin MF. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov. Disord.15(6), 1242–1247 (2000).
   Google Scholar
• Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev. Med. Child Neurol.43(10), 652–657 (2001).
   PubMed Web of Science ®Google Scholar
• van Hilten JJ, Hoff JI, Thang MC, van de Meerakker MM, Voormolen JH, Delhaas EM. Clinimetric issues of screening for responsiveness to intrathecal baclofen in dystonia. J. Neural. Transm.106(9–10), 931–941 (1999).
   Google Scholar
• van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N. Engl. J. Med.343(9), 625–630 (2000).
   PubMedGoogle Scholar
• Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov. Disord.16(6), 1201–1202 (2001).
   Web of Science ®Google Scholar
• Rawicki B. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow-up review of 18 patients. J. Neurosurg.91(5), 733–736 (1999).
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Guin-Renfroe S, Hadley MN. Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Am. J. Phys. Med. Rehabil.78, 247–254 (1999).
   PubMed Web of Science ®Google Scholar
• Gianino JM, York MM, Paice JA, Shott S. Quality of life: effect of reduced spasticity from intrathecal baclofen. J. Neurosci. Nurs.30(1), 47–54 (1998).
   PubMedGoogle Scholar
• Becker WJ, Harris CJ, Long ML, Ablett DP, Klein GM, DeForge DA. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can. J. Neurol. Sci.22(3), 208–217 (1995).
   PubMed Web of Science ®Google Scholar
• Nance P, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer D. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can. J. Neurol. Sci.22(1), 22–29 (1995).
   PubMed Web of Science ®Google Scholar
• Ford B, Greene P, Louis ED et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch. Neurol.53(12), 1241–1246 (1996).
   PubMedGoogle Scholar
• Meythaler JM, Guin-Renfroe S, Grabb P et al. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch. Phys. Med. Rehabil.80, 13–19 (1999).
   PubMed Web of Science ®Google Scholar
• Butler C, Campbell S. AACPDM Treatment outcomes committe review panel: evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev. Med. Child Neurol.42, 634–645 (2000).
   PubMed Web of Science ®Google Scholar
• Penn RD, Savoy SM, Corcos DM et al. Intrathecal baclofen for severe spinal spasticity. N. Eng. J. Med.320, 1517–1521 (1989).
   PubMed Web of Science ®Google Scholar
• Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery33(2), 226–230 (1993).
   PubMedGoogle Scholar
• Silbert PL, Stewart-Wynne EG. Increased dystonia after intrathecal baclofen. Neurology42, 1639–1640 (1992).
   Google Scholar
• Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf.16, 180–204 (1997).
   PubMed Web of Science ®Google Scholar
• Burbaud P, Guehl D, Lagueny A et al. A pilot trial of clozapine in the treatment of cervical dystonia. J. Neurol.245, 329–331 (1998).
   PubMedGoogle Scholar
• Thiel A, Dressler D, Kistel C, Ruther E. Clozapine treatment of spasmodic torticollis. Neurology44, 957–958 (1994).
   PubMed Web of Science ®Google Scholar
• Wolf ME, Mosnaim AD. Improvement of axial dystonia with the administration of clozapine. Int. J. Clin. Pharmacol. Ther.32, 282–283 (1994).
   PubMedGoogle Scholar
• Karp BI, Goldstein SR, Chen R, Samii A, Bara-Jimenez W, Hallett M. An open trial of clozapine for dystonia. Mov. Disord.14(4), 652–657 (1999).
   PubMed Web of Science ®Google Scholar
• Raja M, Maisto G, Altavista MC, Albanese A. Tardive lingual dystonia treated with clozapine. Mov. Disord.11, 585–586 (1996).
   Google Scholar
• Trugman JM, Leadbetter R, Zalis ME, Burgdorf O, Wooten GF. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov. Disord.9, 441–446 (1994).
   Google Scholar
• VanHarten PN, Kamphuis DJ, Matroos GE. Use of clozapine in tardive dystonia. Prog. Neuropsychopharmacol. Biol. Psychiatry20, 263–274 (1996).
   Google Scholar
• Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet347(8994), 127–128 (1996).
   PubMedGoogle Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology48(2), 358–362 (1997).
   PubMed Web of Science ®Google Scholar
• Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur. J. Pharmacol.20, 425–430 (1984).
   Google Scholar
• Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin. Neuropharmacol.27(5), 230–233 (2004).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology38(3), 391–394 (1988).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann. Neurol.11(1), 41–47 (1982).
   PubMed Web of Science ®Google Scholar
• Reches A, Hassan MN, Jackson VR, Fahn S. Lithium attenuates dopamine depleting effects of reserpine and tetrabenzine but not of α methyl-p-tyrosine. Life Sci.33, 157–160 (1983).
   PubMedGoogle Scholar
• Furukawa T, Ushizima I, Ono N. Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine. Psychopharmacologia.42, 243–248 (1975).
   PubMedGoogle Scholar
• Giladi N, Melamed E. Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism. Mov. Disord.14, 158–159 (1999).
   PubMed Web of Science ®Google Scholar
• Pekkenberg H, Fog R. Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both. Arch. Neurol.31, 352–353 (1974).
   PubMedGoogle Scholar
• Hughes AJ, Lees AJ, Marsden CD. Paroxysmal dystonic head tremor. Mov. Disord.6, 85–86 (1991).
   PubMedGoogle Scholar
• Obeso JA, Rothwell JC, Lang AE et al. Myoclonic dystonia. Neurology33, 825–830 (1983).
   PubMed Web of Science ®Google Scholar
• Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology11(Suppl. 9), S6–S10 (1994).
   Google Scholar
• Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs53, 435–452 (1997).
   PubMed Web of Science ®Google Scholar
• Lang AE, Riley DE. Tizanidine in cranial dystonia. Clin. Neuropharmacol.15, 142–147 (1992).
   PubMedGoogle Scholar
• Lucetti C, Nuti A, Gambaccini G et al. Mexiletine in the treatment of torticollis and generalized dystonia. Clin. Neuropharmacol.23, 186–189 (2000).
   Google Scholar
• Ohara S, Hayashi R. Mexiletine in the treatment of spasmodic torticollis. Mov. Disord.13, 934–940 (1998).
   PubMed Web of Science ®Google Scholar
• Ohara S, Tsuyuzaki J, Hayashi R. Mexiletine in the treatment of blepharospasm: experience with the first three patients. Mov. Disord.14, 173–175 (1999).
   PubMed Web of Science ®Google Scholar
• Quinn NP, Rothwell JC, Thompson PD, Marsden CD. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv. Neurol.50, 391–401 (1988).
   Google Scholar
• Muller J, Wenning GK, Wissel J et al. Riluzole therapy in cervical dystonia. Mov. Disord.17(1), 198–200 (2002).
   PubMedGoogle Scholar
• Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev.33(3), 155–188 (1981).
   PubMed Web of Science ®Google Scholar
• Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur. Neurol.53(1), 3–9 (2005).
   PubMed Web of Science ®Google Scholar
• Rossetto O, Seveso M, Caccin P, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon.39(1), 27–41 (2001).
   Google Scholar
• Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve6(Suppl.), S146–S168 (1997).
   PubMedGoogle Scholar
• Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. Mov. Disord.19(Suppl. 8), S53–S59 (2004).
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Kampe K, Bigalke H. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov. Disord.19(Suppl. 8), S65–S67 (2004).
   Google Scholar
• Aoki KR, Guyer B. Botulinum toxin type a and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur. J. Neurol.8(Suppl. 5), 21–29 (2001).
   PubMed Web of Science ®Google Scholar
• Figgitt DP, Noble S. Botulinum toxin B. A review of its therapeutic potential in the management of cervical dystonia. Drugs62, 705–755 (2002).
   PubMedGoogle Scholar
• Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord.19(Suppl. 8), S129–S136 (2004).
   PubMed Web of Science ®Google Scholar
• Comella CL, Pullman SL. Botulinum toxins in neurological disease. Muscle Nerve29(5), 628–44 (2004).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry53(8), 633–639 (1990).
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J. Neurol. Sci.235, 1–9 (2005).
   PubMed Web of Science ®Google Scholar
• Cordivari C, Misra VP, Catania S, Lees AJ. New therapeutic indications for botulinum toxins. Mov. Disord.19(Suppl. 8), S157–S161 (2004).
   Google Scholar
• Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord.9(2), 213–217 (1994).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology45(9), 1743–1746 (1995).
   PubMed Web of Science ®Google Scholar
• Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology43, 1715–1718 (1993).
   PubMed Web of Science ®Google Scholar
• Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J. Neurol. Neurosurg. Psychiatry66(5), 612–616 (1999).
   PubMed Web of Science ®Google Scholar
• Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology50(6), 1624–1629 (1998).
   PubMed Web of Science ®Google Scholar
• Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J. Neurol.246, 265–274 (1999).
   PubMed Web of Science ®Google Scholar
• Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov. Disord.8(4), 479–483 (1993).
   PubMed Web of Science ®Google Scholar
• Mezaki T, Kaji R, Hamano T et al. Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J. Neurol. Neurosurg. Psychiatry57(12), 1535–1537 (1994).
   PubMed Web of Science ®Google Scholar
• Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov. Disord.13(1), 150–154 (1998).
   PubMed Web of Science ®Google Scholar
• Barbano RL. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve24(11), 1567–1568 (2001).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve24(11), 1568–1570 (2001).
   PubMed Web of Science ®Google Scholar
• Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov. Disord.6, 119–126 (1991).
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Tarsy D. Medical therapy for dystonia. In: Handbook of Dystonia. Stacy M (Ed.). Taylor & Francis, NY, USA (2005) (In Press).
   Google Scholar
• Konrad C, Vollmer-Haase J, Anneken K, Knecht S. Orthopedic and neurological complications of cervical dystonia-review of the literature. Acta Neurol. Scand.109, 369–373 (2004).
   PubMed Web of Science ®Google Scholar
• Waterston JA, Swash M, Watkins ES. Idiopathic dystonia and cervical spondylotic myelopathy. J. Neurol. Neurosurg. Psychiatry52, 1424–1426 (1989).
   Google Scholar
• Jahanshahi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. J. Neurol. Neurosurg. Psychiatry55, 229–231 (1992).
   PubMed Web of Science ®Google Scholar
• Lorentz IT, Subramaniam SS, Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov. Disord.6(2), 145–150 (1991).
   PubMed Web of Science ®Google Scholar
• Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov. Disord.12, 100–102 (1997).
   Google Scholar
• Poewe W, Schlosky L, Kleedorfer B et al. Treatment of spasmodic torticollis with local injections of botulinum toxin. J. Neurol.239, 21–25 (1992).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology40(2), 277–280 (1990).
   PubMed Web of Science ®Google Scholar
• Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology40(8), 1213–1218 (1990).
   PubMed Web of Science ®Google Scholar
• Brashear A, Lew MF, Dykstra DD et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology53(7), 1439–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J. Neurol.249(1), 57–63 (2002).
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology39, 80–84 (1989).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology37(4), 616–623 (1987).
   PubMed Web of Science ®Google Scholar
• Cullis PA, O'Brien CF, Truong DD et al. Botulinum toxin type B: an open-label, dose escalation, safety and preliminary efficacy study in cervical dystonia patients. Adv. Neurol.78, 227–230 (1998).
   PubMedGoogle Scholar
• Lew MF, Adornato BT, Duane DD et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology49, 701–707 (1997).
   PubMed Web of Science ®Google Scholar
• Brin MF, Lew MF, Adler CH et al. Safety and efficacy of neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology53(7), 1431–1438 (1999).
   PubMed Web of Science ®Google Scholar
• Barnes MP, Best D, Kidd L et al. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A-initial experiences. Eur. J. Neurol.12(12), 947–955 (2005).
   Google Scholar
• Comella CL, Jankovic J, Shannon KM et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology65, 1423–1429 (2005).
   PubMed Web of Science ®Google Scholar
• Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: Type B compared with type A. Neurology49, 189–194 (1997).
   PubMed Web of Science ®Google Scholar
• Sloop RR, Patel MC. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals. Mov. Disord.16, 100–105 (2001).
   Google Scholar
• Chen R, Karp BI, Hallett M. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology51, 1494–1496 (1998).
   PubMed Web of Science ®Google Scholar
• Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Sampaio C. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst. Rev.CD004312 (2005).
   Google Scholar
• Brans JW, Lindeboom R, Snoek JW et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology46, 1066–1072 (1996).
   PubMed Web of Science ®Google Scholar
• Skogseid IM, Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur. J. Neurol.12, 163–170 (2005).
   PubMed Web of Science ®Google Scholar
• Hsiung G-Y, Das SK, Ranawaya R et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov. Disord.17, 1288–1293 (2002).
   PubMed Web of Science ®Google Scholar
• Dressler D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur. J. Neurol.7, 713–718 (2000).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry75, 951–957 (2004).
   PubMed Web of Science ®Google Scholar
• Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J. Neurol. Neurosurg. Psychiatry72(4), 459–462 (2002).
   PubMed Web of Science ®Google Scholar
• Odergren T, Hjaltason H, Kaakkola S et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry64(1), 6–12 (1998).
   PubMed Web of Science ®Google Scholar
• Poewe W, Deuschl G, Nebe A et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J. Neurol. Neurosurg. Psychiatry64, 13–17 (1998).
   PubMed Web of Science ®Google Scholar
• Comella CL, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology42, 1307–1310 (1992).
   PubMed Web of Science ®Google Scholar
• Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Eur. Neurol.49, 34–38 (2003).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology60, 1186–1188 (2003).
   PubMed Web of Science ®Google Scholar
• Grandas F, Elston J, Quinn N et al. Blepharospasm: a review of 264 patients. J. Neurol. Neurosurg. Psychiatry51, 767–772 (1988).
   PubMed Web of Science ®Google Scholar
• Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov. Disord.17, 7–12 (2002).
   PubMed Web of Science ®Google Scholar
• Kraft SP, Lang AE. Cranial dystonia blepharospasm, and hemifacial spasm: Clinical features and treatment, including the use of botulinum toxin. Can. Med. Assoc. J.139, 837–844 (1988).
   PubMed Web of Science ®Google Scholar
• Taylor JD, Kraft SP, Kazdan MS et al. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can. J. Ophthalmol.26, 133–138 (1991).
   PubMed Web of Science ®Google Scholar
• Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord.2(4), 237–254 (1987).
   PubMed Web of Science ®Google Scholar
• Kennedy RH, Bartley GB, Flanagan JC, Waller RR. Treatment of blepharospasm with botulinum toxin. Mayo. Clin. Proc.64(9), 1085–1090 (1989).
   PubMed Web of Science ®Google Scholar
• Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology95(11), 1529–1534 (1988).
   PubMed Web of Science ®Google Scholar
• Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv. Ophthalmol.41(1), 51–65 (1996).
   PubMed Web of Science ®Google Scholar
• Borodic GE, Cozzolino D. Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast. Reconstr. Surg.83(3), 546–554 (1989).
   Google Scholar
• No authors listed. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. American Academy of Ophthalmology (Suppl.), 37–41 (1989).
   Google Scholar
• American Academy of Neurology. Reports of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Training guidelines for the use of botulinum toxin for the treatment of neurological disorders. Neurology44, 2401–2403 (1994).
   PubMed Web of Science ®Google Scholar
• Truong D. Efficacy and safety of botulinum type A toxin complex (Dysport) for the treatment of benign essential blepharospasm. Parkinsonism Relat. Disord.11(Suppl. 2), 68 (2005).
   Google Scholar
• Frueh BR, Nelson CC, Kapustiak JF, Musch DC. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am. J. Ophthalmol.106(1), 45–47 (1988).
   Google Scholar
• Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch. Ophthalmol.102(10), 1464–1468 (1984).
   PubMedGoogle Scholar
• Sampaio C, Ferreira JJ, Simoes F et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox--assuming a ratio of 4:1. Mov. Disord.12(6), 1013–1018 (1997).
   PubMed Web of Science ®Google Scholar
• Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch. Clin. Exp. Ophthalmol.235(4), 197–199 (1997).
   PubMed Web of Science ®Google Scholar
• Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in rare indications. J. Neurol.248(Suppl. 1), 39–44 (2001).
   Google Scholar
• Tucha O, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol. Scand.103(1), 49–52 (2001).
   PubMed Web of Science ®Google Scholar
• Reimer J, Gilg K, Karow A, Esser J, Franke GH. Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol. Scand.111, 64–70 (2005).
   PubMed Web of Science ®Google Scholar
• Forget R, Tozlovanu V, Iancu A, Boghen D. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology58(12), 1843–1846 (2002).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J. Neurol. Neurosurg. Psychiatry60(6), 704 (1996).
   PubMed Web of Science ®Google Scholar
• Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology104(5), 865–868 (1997).
   PubMed Web of Science ®Google Scholar
• Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J. Neurol.249(1), 64–68 (2002).
   PubMed Web of Science ®Google Scholar
• Silveira-Moriyama L, Goncalves LR, Chien HF, Barbosa ER. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq. Neuropsiquiatr.63(2A), 221–224 (2005).
   PubMed Web of Science ®Google Scholar
• Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J. Neurol. Neurosurg. Psychiatry59(3), 309–311 (1995).
   PubMed Web of Science ®Google Scholar
• Albanese A, Bentivoglio AR, Colosimo C, Galardi G, Maderna L, Tonali P. Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. J. Neurol. Neurosurg. Psychiatry60(6), 693–694 (1996).
   PubMed Web of Science ®Google Scholar
• Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch. Ophthalmol.103(3), 347–350 (1985).
   PubMedGoogle Scholar
• Tolosa E, Kulisevsky J, Fahn S. Meige syndrome: primary and secondary forms. Adv. Neurol.50, 509–515 (1988).
   Google Scholar
• Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch. Otolaryngol. Head Neck Surg.127(4), 389–392 (2001).
   Google Scholar
• Weiner WJ, Nausieda PA, Glantz RH. Meige syndrome (blepharospasm-oromandibular dystonia) after long-term neuroleptic therapy. Neurology31(12), 1555–1556 (1981).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Drug-induced and other orofacial-cervical dyskinesias. Ann. Intern. Med.94(6), 788–793 (1981).
   Google Scholar
• Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology53(9), 2102–2107 (1999).
   PubMed Web of Science ®Google Scholar
• Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope101(11), 1216–1218 (1991).
   Google Scholar
• Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann. Otol. Rhinol. Laryngol.98(2), 93–97 (1989).
   PubMed Web of Science ®Google Scholar
• Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve18(7), 720–729 (1995).
   PubMedGoogle Scholar
• Maurri S, Brogelli S, Alfieri G, Barontini F. Use of botulinum toxin in Meige's disease. Riv. Neurol.58(6), 245–248 (1988).
   Google Scholar
• Laskawi R, Rohrbach S. [Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin]. Laryngorhinootologie.80(12), 708–713 (2001).
   Web of Science ®Google Scholar
• Brin MF. Oromandibular dystonia: Treatment of 96 patients with botulinum toxin type A. In: Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, NY, USA 429–435 (1994).
   Google Scholar
• Behari M, Singh KK, Seshadri S, Prasad K, Ahuja GK. Botulinum toxin A in blepharospasm and hemifacial spasm. J. Assoc. Physicians India42(3), 205–208 (1994).
   Google Scholar
• Berardelli A, Formica A, Mercuri B et al. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Ital. J. Neurol. Sci.14(5), 361–367 (1993).
   Google Scholar
• Aronson AE, Brown JR, Litin EM, Pearson JS. Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J. Speech Hear Disord.33(3), 219–231 (1968).
   PubMedGoogle Scholar
• Aronson AE, Brown JR, Litin EM, Pearson JS. Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects. J. Speech Hear. Disord.33(3), 203–218 (1968).
   PubMedGoogle Scholar
• Leonard R, Kendall K. Differentiation of spasmodic and psychogenic dysphonias with phonoscopic evaluation. Laryngoscope109(2 Pt 1), 295–300 (1999).
   Google Scholar
• Ludlow CL, Connor NP. Dynamic aspects of phonatory control in spasmodic dysphonia. J. Speech Hear. Res.30(2), 197–206 (1987).
   Google Scholar
• Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE. Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope96(11), 1300–1301 (1986).
   PubMedGoogle Scholar
• Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet2(8501), 245–247 (1986).
   PubMed Web of Science ®Google Scholar
• Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can. J. Neurol. Sci.12(4), 314–316 (1985).
   PubMed Web of Science ®Google Scholar
• Rontal M, Rontal E, Rolnick M, Merson R, Silverman B, Truong DD. A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report. Laryngoscope101(8), 911–914 (1991).
   PubMed Web of Science ®Google Scholar
• Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope98(2), 193–197 (1988).
   PubMed Web of Science ®Google Scholar
• Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope101(6 Pt 1), 630–634 (1991).
   PubMedGoogle Scholar
• Ludlow CL, Naunton RF, Terada S, Anderson BJ. Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection. Otolaryngol. Head Neck Surg.104(6), 849–855 (1991).
   Google Scholar
• Whurr R, Lorch M, Fontana H, Brookes G, Lees A, Marsden CD. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J. Neurol. Neurosurg. Psychiatry56(5), 526–530 (1993).
   PubMed Web of Science ®Google Scholar
• Aronson AE, McCaffrey TV, Litchy WJ, Lipton RJ. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections. Laryngoscope103(6), 683–692 (1993).
   PubMed Web of Science ®Google Scholar
• Liu TC, Irish JC, Adams SG, Durkin LC, Hunt EJ. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia. J. Otolaryngol.25(2), 66–74 (1996).
   PubMedGoogle Scholar
• Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J. Speech Lang. Hear. Res.45(3), 469–481 (2002).
   Google Scholar
• Watts CC, Whurr R, Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia. Cochrane Database Syst. Rev.3, CD004327 (2004).
   Google Scholar
• Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int. J. Lang. Commun. Disord.33(Suppl.) 327–329 (1998).
   PubMedGoogle Scholar
• Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia), a 12-year experience in more than 900 patients. Laryngoscope108(10), 1435–1441 (1998).
   PubMed Web of Science ®Google Scholar
• Courey MS, Garrett CG, Billante CR et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann. Otol. Rhinol. Laryngol.109(9), 819–822 (2000).
   PubMed Web of Science ®Google Scholar
• Murry T, Cannito MP, Woodson GE. Spasmodic dysphonia. Emotional status and botulinum toxin treatment. Arch. Otolaryngol. Head Neck Surg.120(3), 310–316 (1994).
   PubMedGoogle Scholar
• Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology38(8), 1220–1225 (1988).
   PubMed Web of Science ®Google Scholar
• Brin MF, Fahn S, Moskowitz C et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv. Neurol.50, 599–608 (1988).
   PubMedGoogle Scholar
• Sheehy MP, Rothwell JC, Marsden CD. Writer's cramp. Adv. Neurol.50, 457–472 (1988).
   Google Scholar
• Thompson PD. Writer's cramp. Br. J. Hosp. Med.50, 91–94 (1993).
   Google Scholar
• Schuele S, Jabusch HC, Lederman RJ, Altenmuller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology64(2), 341–343 (2005).
   PubMed Web of Science ®Google Scholar
• Jabusch HC, Zschucke D, Schmidt A, Schuele S, Altenmuller E. Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients. Mov. Disord.20(12), 1623–1626 (2005).
   PubMed Web of Science ®Google Scholar
• Frucht SJ, Fahn S, Greene PE et al. The natural history of embouchure dystonia. Mov. Disord.16(5), 899–906 (2001).
   Google Scholar
• Turjanski N, Pirtosek Z, Quirk J et al. Botulinum toxin in the treatment of writer's cramp. Clin. Neuropharmacol.19, 314–320 (1996).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz KS. Use of botulinum toxin treatment of hand dystonia. J. Hand Surg.18A, 883–887 (1993).
   Web of Science ®Google Scholar
• Wissel J, Kabus C, Wenzel R et al. Botulinum toxin treatment in writer's cramp: objective response evaluation in 31 patients. J. Neurol. Neurosurg. Psychiatry61, 172–175 (1996).
   PubMed Web of Science ®Google Scholar
• Cohen LG, Hallett M, Geller BD, Hochberg F. Treatment of focal dystonias of the hand with botulinum toxin injections. J. Neurol. Neurosurg. Psychiatry52, 355–363 (1989).
   PubMed Web of Science ®Google Scholar
• Rivest J, Lees AJ, Marsden CD. Writer's cramp: treatment with botulinum toxin injections. Mov. Disord.6, 55–59 (1991).
   PubMed Web of Science ®Google Scholar
• Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov. Disord.10, 466–471 (1995).
   PubMed Web of Science ®Google Scholar
• Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology42, 627–630 (1992).
   PubMed Web of Science ®Google Scholar
• Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double blind study. Neurology43, 183–185 (1993).
   PubMed Web of Science ®Google Scholar
• Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch. Neurol.53, 617–624 (1996).
   PubMedGoogle Scholar
• Bertrand CM, Molina-Negro P. Selective peripheral denervation in 111 cases of spasmodic torticollis. Adv. Neurol.50, 637–643 (1988).
   Google Scholar
• Andrew J, Fowler CJ, Harrison MJG. Stereotaxic thalamotomy in 55 cases of dystonia. Brain106, 981–1000 (1983).
   Google Scholar
• Tasker RR. Surgical treatment of the dystonias. In: Textbook of Stereotactic and Functional Neurosurgery. Gildenberg PL, Tasker RR (Eds). McGraw-Hill, NY, USA 1015–1032 (1998).
   Google Scholar
• Lenz FA, Suarez JI, Metman LV et al. Pallidal activity during dystonia: somatosensory reorganisation and changes with severity. J. Neurol. Neurosurg. Psychiatry65(5), 767–770 (1998).
   Google Scholar
• Vitek JL, Chockkan V, Zhang JY et al. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann. Neurol.46, 22–35 (1999).
   PubMed Web of Science ®Google Scholar
• Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery52, 1358–1370 (2003).
   Google Scholar
• Vitek JL, Zhang JY, DeLong MR, Mewes K, Bakay RAE. GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Adv. Neurol.78, 211–219 (1998).
   Google Scholar
• Silberstein P, Kuhn AA, Kupsch A et al. Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. Brain126, 2597–2608 (2003).
   PubMed Web of Science ®Google Scholar
• DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci.13, 281–285 (1990).
   PubMed Web of Science ®Google Scholar
• Vercueil L, Pollak P, Fraix V et al. Deep brain stimulation in the treatment of severe dystonia. J. Neurol.248(8), 695–700 (2001).
   PubMed Web of Science ®Google Scholar
• Tronnier VM, Fogel W. Pallidal stimulation for generalized dystonia. Report of three cases. J. Neurosurg.92(3), 453–456 (2000).
   PubMed Web of Science ®Google Scholar
• Kumar R, Dagher A, Hutchison WD, Lang AE, Lozano AM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology53(4), 871–874 (1999).
   PubMed Web of Science ®Google Scholar
• Krauss JK, Pohle T, Weber S, Ozdoba C, Burgunder JM. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet354(9181), 837–838 (1999).
   PubMed Web of Science ®Google Scholar
• Lozano AM, Kumar R, Gross RE et al. Globus pallidus internus pallidotomy for generalized dystonia. Mov. Disord.12(6), 865–870 (1997).
   PubMed Web of Science ®Google Scholar
• Vidailhet M, Vercueil L, Houeto JL et al. Bilateral deep brain stimulation of the globus pallidus in primary generalized dystonia. N. Eng. J. Med.352, 459–467 (2005).
   PubMed Web of Science ®Google Scholar
• Merello M, Cerquetti D, Cammarota A et al. Neuronal globus pallidus activity in patients with generalised dystonia. Mov. Disord.19(5), 548–554 (2004).
   Google Scholar
• Krauss JK, Yianni J, Loher TJ, Aziz TZ. Deep brain stimulation for dystonia. J. Clin. Neurophysiol.21(1), 18–30 (2004).
   PubMed Web of Science ®Google Scholar
• Munchau A, Mathen D, Cox T, Quinn NP, Marsden CD, Bhatia KP. Unilateral lesions of the globus pallidus: report of four patients presenting with focal or segmental dystonia. J. Neurol. Neurosurg. Psychiatry69(4), 494–498 (2000).
   PubMed Web of Science ®Google Scholar
• Yianni J, Bain PG, Gregory RP et al. Post-operative progress of dystonia patients following globus pallidus internus deep brain stimulation. Eur. J. Neurol.10(3), 239–247 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar R. Methods for programming and patient management with deep brain stimulation of the globus pallidus for the treatment of advanced Parkinson's disease and dystonia. Mov. Disord.17(Suppl. 3) S198–S207 (2002).
   Web of Science ®Google Scholar
• Volkmann J, Benecke R. Deep brain stimulation for dystonia: patient selection and evaluation. Mov. Disord.17(Suppl. 3) S112–S115 (2002).
   Google Scholar
• Parkin S, Aziz T, Gregory R, Bain P. Bilateral internal globus pallidus stimulation for the treatment of spasmodic torticollis. Mov. Disord.16(3), 489–493 (2001).
   PubMedGoogle Scholar
• Krauss JK, Loher TJ, Pohle T et al. Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy. J. Neurol. Neurosurg. Psychiatry72(2), 249–256 (2002).
   PubMed Web of Science ®Google Scholar
• Bereznai B, Steude U, Seelos K, Botzel K. Chronic high-frequency globus pallidus internus stimulation in different types of dystonia: a clinical, video, and MRI report of six patients presenting with segmental, cervical, and generalized dystonia. Mov. Disord.17(1), 138–144 (2002).
   PubMed Web of Science ®Google Scholar
• Kyriagis M, Grattan-Smith P, Scheinberg A, Teo C, Nakaji N, Waugh M. Status dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and pallidotomy. J. Paediatr. Child Health40(5–6), 322–325 (2004).
   PubMed Web of Science ®Google Scholar
• Angelini L, Nardocci N, Estienne M, Conti C, Dones I, Broggi G. Life-threatening dystonia-dyskinesias in a child: successful treatment with bilateral pallidal stimulation. Mov. Disord.15(5), 1010–1012 (2000).
   Google Scholar
• Vitek JL, Zhang J, Evatt M et al. GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Adv. Neurol.78, 211–219 (1998).
   PubMedGoogle Scholar
• Lin JJ, Lin SZ, Lin GY, Chang DC, Lee CC. Application of bilateral sequential pallidotomy to treat a patient with generalized dystonia. Eur. Neurol.40(2), 108–110 (1998).
   Google Scholar
• Lin JJ, Lin GY, Shih C, Lin SZ, Chang DC, Lee CC. Benefit of bilateral pallidotomy in the treatment of generalized dystonia. Case report. J. Neurosurg.90(5), 974–976 (1999).
   Google Scholar
• Iacono RP, Kuniyoshi SM, Lonser RR, Maeda G, Inae AM, Ashwal S. Simultaneous bilateral pallidoansotomy for idiopathic dystonia musculorum deformans. Pediatr. Neurol.14(2), 145–148 (1996).
   Google Scholar
• Yianni J, Bain P, Giladi N et al. Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov. Disord.18(4), 436–442 (2003).
   PubMed Web of Science ®Google Scholar
• Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet355(9222), 2220–2221 (2000).
   PubMed Web of Science ®Google Scholar
• Cif L, El Fertit H, Vayssiere N et al. Treatment of dystonic syndromes by chronic electrical stimulation of the internal globus pallidus. J. Neurosurg. Sci.47(1), 52–55 (2003).
   PubMedGoogle Scholar
• Eltahawy HA, Saint-Cyr J, Giladi N, Lang AE, Lozano AM. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery54(3), 613–619 (2004).
   PubMed Web of Science ®Google Scholar
• Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov. Disord.21(5), 692–695 (2005) (Epub ahead of print).
   Google Scholar
• Halbig TD, Gruber D, Kopp UA, Schneider GH, Trottenberg T, Kupsch A. Pallidal stimulation in dystonia: effects on cognition, mood, and quality of life. J. Neurol. Neurosurg. Psychiatry76(12), 1713–1716 (2005).
   PubMed Web of Science ®Google Scholar
• Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J. Neurol. Neurosurg. Psychiatry76(9), 1188–1193 (2005).
   PubMed Web of Science ®Google Scholar
• Krause M, Fogel W, Kloss M, Rasche D, Volkmann J, Tronnier V. Pallidal stimulation for dystonia. Neurosurgery55(6), 1361–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Trottenberg T, Paul G, Meissner W, Maier-Hauff K, Taschner C, Kupsch A. Pallidal and thalamic neurostimulation in severe tardive dystonia. J. Neurol. Neurosurg. Psychiatry70(4), 557–559 (2001).
   PubMedGoogle Scholar
• Loher TJ, Hasdemir MG, Burgunder JM, Krauss JK. Long-term follow-up study of chronic globus pallidus internus stimulation for posttraumatic hemidystonia. J. Neurosurg.92(3), 457–460 (2000).
   PubMed Web of Science ®Google Scholar
• Franzini A, Marras C, Ferroli P et al. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases. J. Neurosurg.102(4), 721–725 (2005).
   PubMed Web of Science ®Google Scholar
• Castelnau P, Cif L, Valente EM et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann. Neurol.57(5), 738–741 (2005).
   Google Scholar
• Zorzi G, Marras C, Nardocci N et al. Stimulation of the globus pallidus internus for childhood-onset dystonia. Mov. Disord.20(9), 1194–1200 (2005).
   PubMed Web of Science ®Google Scholar
• Krauss JK, Toups EG, Jankovic J, Grossman RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry63(5), 642–648 (1997).
   PubMed Web of Science ®Google Scholar
• Capelle HH, Weigel R, Krauss JK. Bilateral pallidal stimulation for blepharospasm-oromandibular dystonia (Meige syndrome). Neurology60(12), 2017–2018 (2003).
   PubMed Web of Science ®Google Scholar
• Houser M, Waltz T. Meige syndrome and pallidal deep brain stimulation. Mov. Disord.20(9), 1203–1205 (2005).
   PubMedGoogle Scholar
• Magarinos-Ascone CM, Regidor I, Martinez-Castrillo JC, Gomez-Galan M, Figueiras-Mendez R. Pallidal stimulation relieves myoclonus-dystonia syndrome. J. Neurol. Neurosurg. Psychiatry76(7), 989–991 (2005).
   PubMed Web of Science ®Google Scholar
• Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg. Neurol.40(2), 96–103 (1993).
   PubMed Web of Science ®Google Scholar
• Shima F, Fukui M, Kitamura K, Kuromatsu C, Okamura T. Diagnosis and surgical treatment of spasmodic torticollis of 11th nerve origin. Neurosurgery22(2), 358–363 (1988).
   Web of Science ®Google Scholar
• Friedman AH, Nashold BS Jr., Sharp R, Caputi F, Arruda J. Treatment of spasmodic torticollis with intradural selective rhizotomies. J. Neurosurg.78(1), 46–53 (1993).
   PubMed Web of Science ®Google Scholar
• Krauss JK, Koller R, Burgunder JM. Partial myotomy/myectomy of the trapezius muscle with an asleep-awake-asleep anesthetic technique for treatment of cervical dystonia. Technical note. J. Neurosurg.91(5), 889–891 (1999).
   Google Scholar
• Bara-Jimenez W, Shelton P, Sanger TD, Hallett M. Sensory discrimination capabilities in patients with focal hand dystonia. Ann. Neurol.47(3), 377–380 (2000).
   Google Scholar
• Bara-Jimenez W, Shelton P, Hallett M. Spatial discrimination is abnormal in focal hand dystonia. Neurology55, 1869–1873 (2000).
   Google Scholar
• Byl NN, Merzenich MM, Jenkins WM. A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex ub adult monkeys. Neurology47, 508–520 (1996).
   PubMed Web of Science ®Google Scholar
• Byl NN, Nagajaran S, McKenzie AL. Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: a case series. Arch. Phys. Med. Rehabil.84(10), 1505–1514 (2003).
   PubMed Web of Science ®Google Scholar
• Byl NN, McKenzie A. Treatment effectiveness for patients with a history of repetitive hand use and focal hand dystonia: a planned, prospective follow-up study. J. Hand Ther.13(4), 289–301 (2000).
   PubMedGoogle Scholar
• Zeuner KE, Hallett M. Sensory training as treatment for focal hand dystonia: a 1-year follow-up. Mov. Disord.18(9), 1044–1047 (2003).
   PubMed Web of Science ®Google Scholar
• Zeuner KE, Bara-Jimenez W, Noguchi PS, Goldstein SR, Dambrosia JM, Hallett M. Sensory training for patients with focal hand dystonia. Ann. Neurol.51(5), 593–598 (2002).
   PubMed Web of Science ®Google Scholar
• Zeuner KE, Shill HA, Sohn YH et al. Motor training as treatment in focal hand dystonia. Mov. Disord.20(3), 335–341 (2005).
   Google Scholar
• Bhidayasiri R, Bronstein JM. Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Med. Hypotheses.64(5), 941–945 (2005).
   Google Scholar
• Ranawaya R, Lang A. Usefulness of a writing device in writer's cramp. Neurology41(7), 1136–1138 (1991).
   PubMedGoogle Scholar
• Candia V, Wienbruch C, Elbert T, Rockstroh B, Ray W. Effective behavioral treatment of focal hand dystonia in musicians alters somatosensory cortical organization. Proc. Natl Acad. Sci. USA100(13), 7942–7946 (2003).
   PubMed Web of Science ®Google Scholar
• Tas N, Karatas GK, Sepici V. Hand orthosis as a writing aid in writer's cramp. Mov. Disord.16(6), 1185–1189 (2001).
   PubMed Web of Science ®Google Scholar
• Murase N, Rothwell JC, Kaji R et al. Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex modulates writer's cramp. Brain128(Pt 1), 104–115 (2005).
   PubMedGoogle Scholar
• Pesenti A, Barbieri S, Priori A. Limb immobilization for occupational dystonia: a possible alternative treatment for selected patients. Adv. Neurol.94, 247–254 (2004).
   Google Scholar
• Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov. Disord.16, 7–12 (2001).
   PubMed Web of Science ®Google Scholar
• Priori A, Pesenti A, Cappellari A, Scarlato G, Barbieri S. Limb immobilization for the treatment of focal occupational dystonia. Neurology57(3), 405–409 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kaji R, Kubori T, Kohara N, Iizuka T, Kimura J. Muscle afferent block for the treatment of oromandibular dystonia. Mov. Disord.13(4), 699–705 (1998).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alegre P, Miller VM, Davidson BL, Paulson HL. Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann. Neurol.53(6), 781–787 (2003).
   PubMedGoogle Scholar
• Junker J, Oberwittler C, Jackson D, Berger K. Utilization and perceived effectiveness of complementary and alternative medicine in patients with dystonia. Mov. Disord.19(2), 158–161 (2004).
   PubMed Web of Science ®Google Scholar
• Kock N, Allchorne AJ, Sena-Esteves M, Woolf CJ, Breakefield XO. RNAi blocks DYT1 mutant torsinA inclusions in neurons. Neurosci. Lett.395(3), 201–205 (2006).
   Google Scholar
• Lansbury PT Jr. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Nat. Med.10(Suppl.) S51–S57 (2004).
   PubMed Web of Science ®Google Scholar